Vicenta González

TL;DR: A network of reference centres could potentially support ongoing diagnostic and control efforts made by malaria control programmes in the long term, as the National Centre of Tropical Medicine currently supports the National Programme against Malaria of Equatorial Guinea to perform all of the molecular studies necessary for disease control.

TL;DR: The high level of mutations detected in P. falciparum genes related to SP resistance could be linked to the unsuccessful withdrawal of SP treatment in this area, and drug resistance can reduce the efficacy of intermittent prophylactic treatment with SP for children under 5 years old and for pregnant women.

TL;DR: The present study provides the first evidence of deletion in the pfhrp2 and pFhrp3 genes in P. falciparum isolates from Equatorial Guinea, and it is strongly recommended to implement an active surveillance programme in order to detect any increases in pfHRp 2 and pf hrp3 deletion frequencies.

TL;DR: Current molecular data show an extraordinarily high frequency of drug-resistance mutations in both P. falciparum and P. vivax populations in southern Ethiopia, indicating the need for implementation of entire population access to the new first-line treatment with artemether-lumefantrine to prevent the emergence of resistance to this treatment.

TL;DR: Chloroquine is no longer recommended for malaria treatment in Equatorial Guinea but sulphadoxine-pyrimethamine (SP) remains in use in combination with artesunate and is the only drug recommended in preventive chemotherapy in pregnancy.